Food and Drug Administration of US has approved Firazyr to treat hereditary Angioedema patients. HAP is a swelling in subcutaneous tissues.

The treatment was approved in Europe in 2008, and now has got the approval of FDA for the patients aged above 18 years.

Earlier, CSL’s Berinert and Dyax’s Kalbitor were used for the treatment and only the doctors could give them to the patients but Firazyr will be the first treatment where the patients can inject themselves.

An analyst has estimated that with the introduction of Firazyr, the treatment could make $48 million in sales next year, and by the year 2017, it could generate $199 million.

HAE Association Executive Vice President Janet Long stated the precariousness of HAE attacks can restrict the life of the patients as they cannot travel and lead a healthy social life. “With this approval, patients have an important new option to treat HAE attacks’’, Long said.

According to a FDA statement, Firazyr underwent three trials where patients received aid from the symptoms of attacks within two hours. However, the other medications take almost 20 hours to bring back the stability. The reactions of Firazyr could be fever, giddiness, and rash and increased liver enzymes.